DNA microarray in search of new drug targets for myasthenia gravis

Tali Feferman; Revital Aricha; Renuka Menon; Miriam C. Souroujon; Sonia Berrih-Aknin; Sara Fuchs

doi:10.1196/annals.1381.012

DNA microarray in search of new drug targets for myasthenia gravis

Tali Feferman, Revital Aricha, Renuka Menon, Miriam C. Souroujon, Sonia Berrih-Aknin, Sara Fuchs

Life Sciences discipline

Research output: Chapter in Book/Report/Conference proceeding › Conference contribution › peer-review

Abstract

DNA microarray technology was used to identify new potential drug targets for myasthenia gravis (MG), to delineate genes involved in the pathogenesis of the disease and to possibly target their protein products for immunotherapy. In this study we compared the gene expression in lymph node cells (LNC) and muscles of rats with experimental autoimmune MG (EAMG) to those of control, healthy rats. Of the genes that were found to be deregulated in EAMG, we chose to elaborate on two gene systems: (a) The chemokine IFN-γ-inducible protein 10 (IP-10, CXCL10), and its receptor (CXCR3) and (b) phosphodiesterases.

Original language	English
Title of host publication	Autoimmunity, Part C The Mosaic of Autoimmunity
Publisher	Blackwell Publishing Inc.
Pages	111-117
Number of pages	7
ISBN (Print)	1573316628, 9781573316620
DOIs	https://doi.org/10.1196/annals.1381.012
State	Published - Jun 2007

Publication series

Name	Annals of the New York Academy of Sciences
Volume	1107
ISSN (Print)	0077-8923
ISSN (Electronic)	1749-6632

Keywords

Autoimmunity
Chemokines
Combined therapy
DNA microarray
Myasthenia gravis
Phosphodiesterase

Access to Document

10.1196/annals.1381.012

Cite this

@inproceedings{bbadc56732104901a83469571978a515,

title = "DNA microarray in search of new drug targets for myasthenia gravis",

abstract = "DNA microarray technology was used to identify new potential drug targets for myasthenia gravis (MG), to delineate genes involved in the pathogenesis of the disease and to possibly target their protein products for immunotherapy. In this study we compared the gene expression in lymph node cells (LNC) and muscles of rats with experimental autoimmune MG (EAMG) to those of control, healthy rats. Of the genes that were found to be deregulated in EAMG, we chose to elaborate on two gene systems: (a) The chemokine IFN-γ-inducible protein 10 (IP-10, CXCL10), and its receptor (CXCR3) and (b) phosphodiesterases.",

keywords = "Autoimmunity, Chemokines, Combined therapy, DNA microarray, Myasthenia gravis, Phosphodiesterase",

author = "Tali Feferman and Revital Aricha and Renuka Menon and Souroujon, {Miriam C.} and Sonia Berrih-Aknin and Sara Fuchs",

year = "2007",

month = jun,

doi = "10.1196/annals.1381.012",

language = "אנגלית",

isbn = "1573316628",

series = "Annals of the New York Academy of Sciences",

publisher = "Blackwell Publishing Inc.",

pages = "111--117",

booktitle = "Autoimmunity, Part C The Mosaic of Autoimmunity",

}

DNA microarray in search of new drug targets for myasthenia gravis. / Feferman, Tali; Aricha, Revital; Menon, Renuka et al.
Autoimmunity, Part C The Mosaic of Autoimmunity. Blackwell Publishing Inc., 2007. p. 111-117 (Annals of the New York Academy of Sciences; Vol. 1107).

Research output: Chapter in Book/Report/Conference proceeding › Conference contribution › peer-review

TY - GEN

T1 - DNA microarray in search of new drug targets for myasthenia gravis

AU - Feferman, Tali

AU - Aricha, Revital

AU - Menon, Renuka

AU - Souroujon, Miriam C.

AU - Berrih-Aknin, Sonia

AU - Fuchs, Sara

PY - 2007/6

Y1 - 2007/6

N2 - DNA microarray technology was used to identify new potential drug targets for myasthenia gravis (MG), to delineate genes involved in the pathogenesis of the disease and to possibly target their protein products for immunotherapy. In this study we compared the gene expression in lymph node cells (LNC) and muscles of rats with experimental autoimmune MG (EAMG) to those of control, healthy rats. Of the genes that were found to be deregulated in EAMG, we chose to elaborate on two gene systems: (a) The chemokine IFN-γ-inducible protein 10 (IP-10, CXCL10), and its receptor (CXCR3) and (b) phosphodiesterases.

AB - DNA microarray technology was used to identify new potential drug targets for myasthenia gravis (MG), to delineate genes involved in the pathogenesis of the disease and to possibly target their protein products for immunotherapy. In this study we compared the gene expression in lymph node cells (LNC) and muscles of rats with experimental autoimmune MG (EAMG) to those of control, healthy rats. Of the genes that were found to be deregulated in EAMG, we chose to elaborate on two gene systems: (a) The chemokine IFN-γ-inducible protein 10 (IP-10, CXCL10), and its receptor (CXCR3) and (b) phosphodiesterases.

KW - Autoimmunity

KW - Chemokines

KW - Combined therapy

KW - DNA microarray

KW - Myasthenia gravis

KW - Phosphodiesterase

UR - http://www.scopus.com/inward/record.url?scp=34648832290&partnerID=8YFLogxK

U2 - 10.1196/annals.1381.012

DO - 10.1196/annals.1381.012

M3 - ???researchoutput.researchoutputtypes.contributiontobookanthology.conference???

C2 - 17804538

AN - SCOPUS:34648832290

SN - 1573316628

SN - 9781573316620

T3 - Annals of the New York Academy of Sciences

SP - 111

EP - 117

BT - Autoimmunity, Part C The Mosaic of Autoimmunity

PB - Blackwell Publishing Inc.

ER -

DNA microarray in search of new drug targets for myasthenia gravis

Abstract

Publication series

Keywords

Access to Document

Other files and links

Fingerprint

Cite this